Want to see IN:ASTEC full AI Analyst Report?
Top Page
Astec Lifesciences Limited
(ASTEC)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹798.00
▲(13.43% Upside)
Action:Reiterated
Date:09/23/26
The score is held back primarily by weak financial performance—sustained losses, higher leverage, and recent cash burn (including negative operating cash flow in FY26). This is partially offset by strong technical momentum with the stock trading well above major moving averages and a positive MACD, while valuation remains pressured due to a negative P/E and no indicated dividend yield.
Positive Factors
FY26 Revenue Recovery
The 18.5% FY26 revenue rebound indicates that top-line demand recovered after two difficult years. If maintained, stronger volumes or pricing could improve fixed-cost absorption and create a foundation for restoring profitability, although margins remain weak.
Negative Factors
Sustained Large Losses
The shift from positive earnings to sizable losses across FY24–FY26 indicates that the recent revenue rebound has not translated into viable profitability. Persistent negative operating profit can constrain reinvestment, weaken resilience, and make recovery dependent on a material earnings improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
FY26 Revenue Recovery
The 18.5% FY26 revenue rebound indicates that top-line demand recovered after two difficult years. If maintained, stronger volumes or pricing could improve fixed-cost absorption and create a foundation for restoring profitability, although margins remain weak.
Read all positive factors
Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)
Market Cap
₹17.69B
Dividend Yield0.12%
Average Volume (3M)17.72K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth9.33%
EPS Growth53.30%
CountryIN
Employees471
SectorGeneral
Sector StrengthN/A
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-30.27
Shares Outstanding22,282,820
10 Day Avg. Volume14,000
30 Day Avg. Volume17,716
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)2.96
Price to Sales (P/S)2.58
P/FCF Ratio-9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-15.1
Revenue Forecast (FY)₹5.64B
Astec Lifesciences Limited Business Overview & Revenue Model
Company Description
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the...
How the Company Makes Money
ASTEC primarily makes money by manufacturing and selling agrochemical active ingredients (technical-grade crop protection chemicals) and chemical intermediates used by formulators and agrochemical companies to produce finished crop protection prod...
Astec Lifesciences Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.41B | 4.48B | 3.81B | 4.58B | 6.28B | 6.77B |
| Gross Profit | 552.59M | 419.01M | -685.16M | 1.33B | 2.27B | 2.86B |
| EBITDA | 89.92M | -15.49M | -662.07M | -2.69M | 893.14M | 1.65B |
| Net Income | -665.97M | -809.17M | -1.35B | -469.30M | 255.65M | 898.59M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 9.42B | 8.81B | 9.75B | 9.79B | 8.97B |
| Cash, Cash Equivalents and Short-Term Investments | 100.49M | 122.51M | 8.55M | 16.47M | 27.54M | 33.44M |
| Total Debt | 0.00 | 4.49B | 5.55B | 4.94B | 3.41B | 2.79B |
| Total Liabilities | -3.91B | 5.51B | 6.46B | 6.05B | 5.60B | 5.00B |
| Stockholders Equity | 3.91B | 3.91B | 2.35B | 3.69B | 4.19B | 3.96B |
Cash Flow | ||||||
| Free Cash Flow | -234.96M | -1.18B | -302.20M | -1.25B | -426.03M | -803.74M |
| Operating Cash Flow | -199.52M | -1.13B | -83.99M | 102.21M | 746.56M | 236.04M |
| Investing Cash Flow | -73.41M | -49.07M | -152.30M | -1.35B | -1.13B | -1.04B |
| Financing Cash Flow | 297.62M | 1.27B | 237.33M | 1.25B | 377.70M | 804.77M |
Astec Lifesciences Limited Technical Analysis
Positive
703.50
Price Trends
642.68
Positive
688.56
Positive
669.19
Positive
Market Momentum
35.30
Negative
57.73
Neutral
53.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Positive. The current price of 703.5 is above the 20-day moving average (MA) of 667.45, above the 50-day MA of 642.68, and above the 200-day MA of 669.19, indicating a bullish trend. The MACD of 35.30 indicates Negative momentum. The RSI at 57.73 is Neutral, neither overbought nor oversold. The STOCH value of 53.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ASTEC.
Astec Lifesciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹67.53B | 10.92 | ― | 1.98% | 18.52% | 49.11% | |
67 Neutral | ₹18.75B | 8.31 | ― | 0.04% | -5.17% | 4.24% | |
67 Neutral | ₹42.99B | 16.53 | ― | 0.20% | -5.63% | -11.38% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹17.80B | 13.86 | ― | 0.33% | 1.26% | -16.43% | |
55 Neutral | ₹15.38B | 14.30 | ― | 0.56% | 17.05% | 9.10% | |
51 Neutral | ₹17.69B | -25.02 | ― | 0.12% | 9.33% | 53.30% |
* General Sector Average
IN:ASTEC
Astec Lifesciences Limited
736.70
-78.30
-9.61%
IN:BHARATRAS
Bharat Rasayan Limited
1,095.50
-1,385.88
-55.85%
IN:DHANUKA
Dhanuka Agritech Limited
966.50
-532.91
-35.54%
IN:INSECTICID
Insecticides (India) Limited
608.40
-150.48
-19.83%
IN:IPL
India Pesticides Ltd.
133.85
-73.63
-35.49%
IN:SHARDACROP
Sharda Cropchem Ltd.
750.00
-64.87
-7.96%
Astec Lifesciences Limited Corporate Events
Astec LifeSciences shareholders clear board changes and related-party deals via postal ballot
Jul 4, 2026
Astec LifeSciences Limited said shareholders approved multiple board-level appointments and changes via a postal ballot, with all resolutions passed by the requisite majority following e-voting. The company confirmed the addition of non-executive ...
Astec LifeSciences Shareholders Clear Board Changes and Key Godrej Group Transactions
Jul 4, 2026
Astec LifeSciences Limited has reported that shareholders have approved all resolutions proposed through a recent postal ballot and e-voting process, as confirmed by the scrutinizer’s report dated 4 July 2026. The measures include the appoin...
Astec Lifesciences Overhauls Board, Clears Key Godrej Group Transactions via Postal Ballot
Jul 4, 2026
Astec LifeSciences Limited said shareholders have approved a slate of boardroom changes and related party arrangements through a postal ballot, with all resolutions passed by the requisite majority via e-voting. The approvals include appointing Vi...
Astec LifeSciences Reshapes Board and Clears Key Godrej Group Transactions
Jul 4, 2026
Astec LifeSciences has secured shareholder approval via postal ballot and e-voting for a comprehensive reshaping of its board and governance framework. Investors backed the appointment of Vishal Sharma and Burjis N. Godrej as non‑executive, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.